| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Tudor Pop
Rosalio Madrigal
Tudor Pop
Michael Rose
Michael Rose
| Share Statistics | AUPH | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,289.8 | $241.2 | 57% |
|
| Shares Out (Mil) | 133.5 | 53.4 | 68% |
|
| Institutional Ownership | 96.7% | 92.9% | 71% |
|
| Float (Mil) | 129.2 | 41.2 | 65% |
|
| Beta | 1.41 | 0.96 | 80% |
|
| Avg Daily Volume (000s) | 676 | 486 | 63% |
|
| Price Change (52-week) |
36.3% | 48.4% | 79% |
|
| Growth | AUPH | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 41.4% | 12.8% | 94% |
|
| Net Income (5yr) | 36.8% | (10.1%) | 89% |
|
| EPS (5yr) | 34.4% | 15.8% | 85 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 41.0% | (15.7%) | 91% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | na | |
| Current EPS | $0.220 | $0.948 | na | |
| Month Ago EPS | $0.220 | $0.944 | na | |
| # Rev Up | na | 1 | na | |
| # Rev Down | na | 0 | na | |
| Three Months Ago EPS | $0.238 | $0.950 | na | |
| Year/Year Chg | (21.4%) | (54.2%) | (34.1%) | |
| Financials | AUPH | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $312 | $37 | 36% |
|
| Net Income (TTM) (Mil) | $314 | ($44) | 73% |
|
| EPS (TTM) | $2.388 | ($1.600) | 74% |
|
| Operating Cash Flow (TTM) (Mil) | $175 | ($33) | 58% |
|
| Net Cash Flow (TTM) (Mil) | $127 | $3 | 79% |
|
| Long-Term Debt (Q1) (Mil) | $46 | $4 | 38% |
|
| Enterprise Value (Q1) (Mil) | $1,870 | $177 | 48% |
|
| Valuation | AUPH | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.72 | 2.25 | 73% |
|
| P/E | 7.5 | 20.2 | 9% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.2 | 1.0 | 9% |
|
| Ratios | AUPH | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 77.9% | 66.9% | 87% |
|
| Net Margin | 100.8% | (73.7%) | 99% |
|
| ROA | 48.5% | (47.3%) | 99% |
|
| ROE | 66.1% | (53.3%) | 94% |
|
| Liabilities to Assets | 22.4% | 29.7% | 15% |
|
| F-Score | 7 | 2 | 82% |
|
Passing Stock Screens
As of 10/29/2026, from a list of 60 stock screening strategies,
| Performance Since Inception: | 6.3% |
| +/- S&P 500: | -1.2 |
| Performance Since Inception: | 12.9% |
| +/- S&P 500: | +5.4 |
| Performance Since Inception: | 13.0% |
| +/- S&P 500: | +5.5 |
| Performance Since Inception: | 12.7% |
| +/- S&P 500: | +5.2 |
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors
